for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Instil Bio Inc

TIL.OQ

Latest Trade

21.50USD

Change

0.52(+2.48%)

Volume

95,969

Today's Range

20.80

 - 

21.87

52 Week Range

14.49

 - 

29.49

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
20.98
Open
21.00
Volume
95,969
3M AVG Volume
5.19
Today's High
21.87
Today's Low
20.80
52 Week High
29.49
52 Week Low
14.49
Shares Out (MIL)
128.76
Market Cap (MIL)
2,616.44
Forward P/E
-16.14
Dividend (Yield %)
--

Latest Developments

More

Instil Bio Gets Clearance For Phase 2 Trial For Patients With Advanced Melanoma

Instil Bio Reports Second Quarter 2021 Financial Results And Provides Corporate Update

Instil Bio Inc Shares Open 35% Above IPO Price in Nasdaq Debut

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Instil Bio Inc

Instil Bio, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing cell therapy pipeline of autologous tumor infiltrating lymphocyte (TIL) therapies for the treatment of patients with cancer. It is advancing its lead TIL product candidate, ITIL-168, for the treatment of advanced melanoma. It is also developing a class of genetically engineered TIL therapies using its Co-Stimulatory Antigen Receptor (CoStAR) platform. ITIL-168 is an autologous TIL therapy that it is initially developing for the treatment of PD-1-inhibitor relapsed or refractory advanced melanoma. Its pipeline also includes ITIL-306, its lead CoStAR-TIL product candidate. ITIL-306, expresses a CoStAR molecule designed to recognize folate receptor alpha (FOLR1), a tumor-associated antigen that is expressed on numerous solid tumors, including ovarian cancer, uterine cancer, NSCLC and renal cancer.

Industry

Business Services

Contact Info

3963 Maple Avenue, Suite 350

DALLAS, TX

75219

United States

+1.972.4993350

https://instilbio.com/

Executive Leadership

Bronson Crouch

Chairman of the Board, Chief Executive Officer

Sandeep Laumas

Chief Financial Officer, Chief Business Officer

Vijay Chiruvolu

Chief Technology Officer

Zachary Roberts

Chief Medical Officer

Neil W. Gibson

Lead Independent Director

Key Stats

1.80 mean rating - 5 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2021(E)

0.0K
EPS (USD)

2021(E)

-1.300
Price To Earnings (TTM)
--
Price To Sales (TTM)
--
Price To Book (MRQ)
4.12
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
--
Return on Equity (TTM)
--

Latest News

Latest News

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up